That's why there are competing BP so if another BP other than Roche want to break into the same cancer market then HER-Vaxx will be attractive to them. As you are aware, not all cancer patients respond the same to treatment even with the current commercial drugs and as shown in IMU's clinical trial but I think BP are pivoting away from full chemotherapy treatment and looking to invest in alternate cancer treatment.
Your believe is totally opposite to LC and YF so we will see who is right, noting LC was also very confident on releasing the first clinical trial update for VAXINIA 15 months which demonstrated efficacy when you even stated was excellent to achieve CR (they also showed multiple SD and PR) but misleadingly stated that management was increasing dosage as they weren't seeing efficacy.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)